MAGE-A1-specific T cell receptor-transduced autologous T-cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MAGE-A1-specific T cell receptor-transduced autologous T-cells, covering 2023-08-03 to 2023-08-03. Get the full timeline:
Most recent: Clinical Trial Update: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer [Phase 1, Phase 2]